{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:45Z","timestamp":1792788165009,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201810-2017419"],"award-info":[{"award-number":["201810-2017419"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010146","name":"Alzheimer Forschung Initiative","doi-asserted-by":"publisher","award":["20026"],"award-info":[{"award-number":["20026"]}],"id":[{"id":"10.13039\/100010146","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert-Koch Institut","award":["1369\u2013341"],"award-info":[{"award-number":["1369\u2013341"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP16\/00041 and PI19\/00144"],"award-info":[{"award-number":["CP16\/00041 and PI19\/00144"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer\u2019s disease in reactive microglia and astrocytes. Plasma Lipocalin-2 has been proposed as a biomarker for Alzheimer\u2019s disease but available data is scarce and inconsistent. Thus, we evaluated plasma Lipocalin-2 in the context of Alzheimer\u2019s disease, differential diagnoses, other biomarkers, and clinical data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      For this two-center case-control study, we analyzed Lipocalin-2 concentrations in plasma samples from a cohort of\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009407 individuals. The diagnostic groups comprised Alzheimer\u2019s disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200974), vascular dementia (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928), other important differential diagnoses (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009221), and healthy controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200984). Main results were validated in an independent cohort with patients with Alzheimer\u2019s disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919), mild cognitive impairment (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927), and healthy individuals (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma Lipocalin-2 was significantly lower in Alzheimer\u2019s disease compared to healthy controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and all other groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) except for mixed dementia (vascular and Alzheimer\u2019s pathologic changes). Areas under the curve from receiver operation characteristics for the discrimination of Alzheimer\u2019s disease and healthy controls were 0.783 (95%CI: 0.712\u20130.855) in the study cohort and 0.766 (95%CI: 0.627\u20130.905) in the validation cohort. The area under the curve for Alzheimer\u2019s disease versus vascular dementia was 0.778 (95%CI: 0.667\u20130.890) in the study cohort. In Alzheimer\u2019s disease patients, plasma Lipocalin2 did not show significant correlation with cerebrospinal fluid biomarkers of neurodegeneration and AD-related pathology (total-tau, phosphorylated tau protein, and beta-amyloid 1-42), cognitive status (Mini Mental Status Examination scores), APOE genotype, or presence of white matter hyperintensities. Interestingly, Lipocalin 2 was lower in patients with rapid disease course compared to patients with non-rapidly progressive Alzheimer\u2019s disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma Lipocalin-2 has potential as a diagnostic biomarker for Alzheimer\u2019s disease and seems to be independent from currently employed biomarkers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-021-00955-9","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T13:02:55Z","timestamp":1642078975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma Lipocalin 2 in Alzheimer\u2019s disease: potential utility in the differential diagnosis and relationship with other biomarkers"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-8325","authenticated-orcid":false,"given":"Peter","family":"Hermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Villar-Piqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Varges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Bunck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Baldeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Riggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"955_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"955_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0.","journal-title":"Lancet Neurol"},{"key":"955_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"955_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/15622975.2017.1375556","volume":"19","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Riederer P, O\u2019Bryant SE, Verbeek MM, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19:244\u2013328. https:\/\/doi.org\/10.1080\/15622975.2017.1375556.","journal-title":"World J Biol Psychiatry"},{"key":"955_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su\u00e1rez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429\u201342. https:\/\/doi.org\/10.1038\/s41380-020-00923-z.","journal-title":"Mol Psychiatry"},{"key":"955_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1.","journal-title":"Nat Med"},{"key":"955_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, et al. Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study. Brain. 2020;143:1220\u201332. https:\/\/doi.org\/10.1093\/brain\/awaa054.","journal-title":"Brain"},{"key":"955_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med. 2019;25:277\u201383. https:\/\/doi.org\/10.1038\/s41591-018-0304-3.","journal-title":"Nat Med"},{"key":"955_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 2017;74:1073\u201380. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1359.","journal-title":"JAMA Neurol"},{"key":"955_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Bendlin BB. Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26:296\u2013308. https:\/\/doi.org\/10.1038\/s41380-020-0721-9.","journal-title":"Mol Psychiatry"},{"key":"955_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-nutr-071816-064559","volume":"37","author":"X Xiao","year":"2017","unstructured":"Xiao X, Yeoh BS, Vijay-Kumar M. Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr. 2017;37:103\u201330. https:\/\/doi.org\/10.1146\/annurev-nutr-071816-064559.","journal-title":"Annu Rev Nutr"},{"key":"955_CR12","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/glia.23174","volume":"65","author":"JH Kim","year":"2017","unstructured":"Kim JH, Ko PW, Lee HW, Jeong JY, Lee MG, Kim JH, et al. Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. Glia. 2017;65:1471\u201390. https:\/\/doi.org\/10.1002\/glia.23174.","journal-title":"Glia"},{"key":"955_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41467-020-14373-2","volume":"11","author":"F Llorens","year":"2020","unstructured":"Llorens F, Hermann P, Villar-Piqu\u00e9 A, Diaz-Lucena D, N\u00e4gga K, Hansson O, et al. Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nat Commun. 2020;11:619. https:\/\/doi.org\/10.1038\/s41467-020-14373-2.","journal-title":"Nat Commun"},{"key":"955_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2021.07.001","volume":"107","author":"PJW Naud\u00e9","year":"2021","unstructured":"Naud\u00e9 PJW, Ramakers IHGB, van der Flier WM, Jiskoot LC, Reesink FE, Claassen JAHR, et al. Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. Neurobiol Aging. 2021;107:1\u201310. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.07.001.","journal-title":"Neurobiol Aging"},{"key":"955_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1053\/j.ajkd.2020.05.015","volume":"76","author":"C Albert","year":"2020","unstructured":"Albert C, Zapf A, Haase M, R\u00f6ver C, Pickering JW, Albert A, et al. Neutrophil gelatinase-associated lipocalin measured on clinical laboratory platforms for the prediction of acute kidney injury and the associated need for dialysis therapy: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76:826\u201341.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2020.05.015.","journal-title":"Am J Kidney Dis"},{"key":"955_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tem.2017.01.003","volume":"28","author":"AR Moschen","year":"2017","unstructured":"Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab. 2017;28:388\u201397. https:\/\/doi.org\/10.1016\/j.tem.2017.01.003.","journal-title":"Trends Endocrinol Metab"},{"key":"955_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7762\/cnr.2018.7.1.1","volume":"7","author":"J Song","year":"2018","unstructured":"Song J, Kim OY. Perspectives in lipocalin-2: emerging biomarker for medical diagnosis and prognosis for Alzheimer\u2019s disease. Clin Nutr Res. 2018;7:1\u201310. https:\/\/doi.org\/10.7762\/cnr.2018.7.1.1.","journal-title":"Clin Nutr Res"},{"key":"955_CR18","doi-asserted-by":"publisher","first-page":"663837","DOI":"10.3389\/fnagi.2021.663837","volume":"13","author":"SP das Neves","year":"2021","unstructured":"das Neves SP, Taipa R, Marques F, Soares Costa P, Mon\u00e1rrez-Espino J, Palha JA, et al. Association between iron-related protein lipocalin 2 and cognitive impairment in cerebrospinal fluid and serum. Front Aging Neurosci. 2021;13:663837. https:\/\/doi.org\/10.3389\/fnagi.2021.663837.","journal-title":"Front Aging Neurosci"},{"key":"955_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jns.2011.03.023","volume":"305","author":"J Choi","year":"2011","unstructured":"Choi J, Lee HW, Suk K. Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci. 2011;305:28\u201333. https:\/\/doi.org\/10.1016\/j.jns.2011.03.023.","journal-title":"J Neurol Sci"},{"key":"955_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.dadm.2019.07.004","volume":"11","author":"E Eruysal","year":"2019","unstructured":"Eruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M. Plasma lipocalin-2 levels in the preclinical stage of Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2019;11:646\u201353. https:\/\/doi.org\/10.1016\/j.dadm.2019.07.004.","journal-title":"Alzheimers Dement (Amst)"},{"key":"955_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.str.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sj\u00f6gren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318\u201322. https:\/\/doi.org\/10.1161\/01.str.32.6.1318.","journal-title":"Stroke"},{"key":"955_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"955_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347. https:\/\/doi.org\/10.1212\/WNL.0000000000002923.","journal-title":"Neurology"},{"key":"955_CR24","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/archneurol.2011.189.30","volume":"68","author":"C Schmidt","year":"2011","unstructured":"Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68:1124\u201330. https:\/\/doi.org\/10.1001\/archneurol.2011.189.30.","journal-title":"Arch Neurol"},{"key":"955_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"955_CR26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2017.09.007","volume":"14","author":"OA Skrobot","year":"2018","unstructured":"Skrobot OA, Black SE, Chen C, DeCarli C, Erkinjuntti T, Ford GA, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018;14:280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2017.09.007.","journal-title":"Alzheimers Dement"},{"key":"955_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","volume":"20","author":"P Hermann","year":"2021","unstructured":"Hermann P, Appleby B, Brandel JP, Caughey B, Collins S, Geschwind MD, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021;20:235\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(20)30477-4.","journal-title":"Lancet Neurol"},{"key":"955_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058.","journal-title":"Neurology"},{"key":"955_CR29","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain"},{"key":"955_CR30","doi-asserted-by":"publisher","first-page":"e1003289","DOI":"10.1371\/journal.pmed.1003289","volume":"17","author":"H Saddiki","year":"2020","unstructured":"Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E genotype and Alzheimer disease: a cerebrospinal fluid biomarker-based case-control study. PLoS Med. 2020;17:e1003289. https:\/\/doi.org\/10.1371\/journal.pmed.1003289.","journal-title":"PLoS Med"},{"key":"955_CR31","volume-title":"Multiple comparisons using R","author":"F Bretz","year":"2010","unstructured":"Bretz F, Hothorn T, Westfall P. Multiple comparisons using R. Boca Raton: CRC Press; 2010."},{"key":"955_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-021-00815-6","volume":"13","author":"I Zerr","year":"2021","unstructured":"Zerr I, Villar-Piqu\u00e9 A, Hermann P, Schmitz M, Varges D, Ferrer I, et al. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther. 2021;13:86. https:\/\/doi.org\/10.1186\/s13195-021-00815-6.","journal-title":"Alzheimers Res Ther"},{"key":"955_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","volume":"16","author":"A Villar-Piqu\u00e9","year":"2019","unstructured":"Villar-Piqu\u00e9 A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16:145. https:\/\/doi.org\/10.1186\/s12974-019-1531-3.","journal-title":"J Neuroinflammation"},{"key":"955_CR34","doi-asserted-by":"publisher","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer's disease. Brain. 2021:awab223. https:\/\/doi.org\/10.1093\/brain\/awab223 Epub ahead of print.","DOI":"10.1093\/brain\/awab223"},{"key":"955_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ana.25385","volume":"85","author":"T Ohara","year":"2019","unstructured":"Ohara T, Hata J, Tanaka M, Honda T, Yamakage H, Yoshida D, et al. Serum soluble triggering receptor expressed on myeloid cells 2 as a biomarker for incident dementia: the Hisayama study. Ann Neurol. 2019;85:47\u201358. https:\/\/doi.org\/10.1002\/ana.25385.","journal-title":"Ann Neurol"},{"key":"955_CR36","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1096\/fj.11-202457","volume":"26","author":"PJ Naud\u00e9","year":"2012","unstructured":"Naud\u00e9 PJ, Nyakas C, Eiden LE, Ait-Ali D, van der Heide R, Engelborghs S, et al. Lipocalin 2: novel component of proinflammatory signaling in Alzheimer\u2019s disease. FASEB J. 2012;26:2811\u201323. https:\/\/doi.org\/10.1096\/fj.11-202457.","journal-title":"FASEB J"},{"key":"955_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(19)30368-0.","journal-title":"Lancet Neurol"},{"key":"955_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"key":"955_CR39","doi-asserted-by":"publisher","first-page":"e96997","DOI":"10.1371\/journal.pone.0096997","volume":"9","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Foncea R, Deis JA, Guo H, Bernlohr DA, Chen X. Lipocalin 2 expression and secretion is highly regulated by metabolic stress, cytokines, and nutrients in adipocytes. PLoS One. 2014;9:e96997. https:\/\/doi.org\/10.1371\/journal.pone.0096997.","journal-title":"PLoS One"},{"key":"955_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/jcla.21662","volume":"28","author":"TS Itenov","year":"2014","unstructured":"Itenov TS, Bangert K, Christensen PH, Jensen JU, Bestle MH, Procalcitonin and Survival Study (PASS)-study group. Serum and plasma neutrophil gelatinase associated lipocalin (NGAL) levels are not equivalent in patients admitted to intensive care. J Clin Lab Anal. 2014;28:163\u20137. https:\/\/doi.org\/10.1002\/jcla.21662.","journal-title":"J Clin Lab Anal"},{"key":"955_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1615\/critrevimmunol.2015012127","volume":"35","author":"S Lee","year":"2015","unstructured":"Lee S, Jha MK, Suk K. Lipocalin-2 in the inflammatory activation of brain astrocytes. Crit Rev Immunol. 2015;35:77\u201384. https:\/\/doi.org\/10.1615\/critrevimmunol.2015012127.","journal-title":"Crit Rev Immunol"},{"key":"955_CR42","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/ijms20061271","volume":"20","author":"F Ranjbar Taklimie","year":"2019","unstructured":"Ranjbar Taklimie F, Gasterich N, Scheld M, Weiskirchen R, Beyer C, Clarner T, et al. Hypoxia induces astrocyte-derived lipocalin-2 in ischemic stroke. Int J Mol Sci. 2019;20:1271. https:\/\/doi.org\/10.3390\/ijms20061271.","journal-title":"Int J Mol Sci"},{"key":"955_CR43","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/jcmm.12538","volume":"19","author":"G Wang","year":"2015","unstructured":"Wang G, Weng YC, Han X, Whaley JD, McCrae KR, Chou WH. Lipocalin-2 released in response to cerebral ischaemia mediates reperfusion injury in mice. J Cell Mol Med. 2015;19:1637\u201345. https:\/\/doi.org\/10.1111\/jcmm.12538.","journal-title":"J Cell Mol Med"},{"key":"955_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00401-017-1738-2","volume":"134","author":"KE McAleese","year":"2017","unstructured":"McAleese KE, Walker L, Graham S, Moya ELJ, Johnson M, Erskine D, et al. Parietal white matter lesions in Alzheimer\u2019s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol. 2017;134:459\u201373. https:\/\/doi.org\/10.1007\/s00401-017-1738-2.","journal-title":"Acta Neuropathol"},{"key":"955_CR45","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/cdd.2014.68","volume":"21","author":"SD Mesquita","year":"2014","unstructured":"Mesquita SD, Ferreira AC, Falcao AM, Sousa JC, Oliveira TG, Correia-Neves M, et al. Lipocalin 2 modulates the cellular response to amyloid beta. Cell Death Differ. 2014;21:1588\u201399. https:\/\/doi.org\/10.1038\/cdd.2014.68.","journal-title":"Cell Death Differ"},{"key":"955_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12974-018-1372-5","volume":"15","author":"DW Dekens","year":"2018","unstructured":"Dekens DW, Naud\u00e9 PJW, Keijser JN, Boerema AS, De Deyn PP, Eisel ULM. Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model. J Neuroinflammation. 2018;15:330. https:\/\/doi.org\/10.1186\/s12974-018-1372-5.","journal-title":"J Neuroinflammation"},{"key":"955_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12974-020-01750-3","volume":"17","author":"KK Bawa","year":"2020","unstructured":"Bawa KK, Krance SH, Herrmann N, Cogo-Moreira H, Ouk M, Yu D, et al. A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer\u2019s disease. J Neuroinflammation. 2020;17:84. https:\/\/doi.org\/10.1186\/s12974-020-01750-3.","journal-title":"J Neuroinflammation"},{"key":"955_CR48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pneurobio.2015.06.005","volume":"131","author":"AC Ferreira","year":"2015","unstructured":"Ferreira AC, D\u00e1 Mesquita S, Sousa JC, Correia-Neves M, Sousa N, Palha JA, et al. From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol. 2015;131:120\u201336. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.06.005.","journal-title":"Prog Neurobiol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00955-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00955-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T13:03:05Z","timestamp":1642078985000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00955-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00955-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and was approved by Ethic committees in the University Medical Center, G\u00f6ttingen, Germany (Reference numbers: 11\/11\/93, 34\/9\/07, 6\/9\/08, 19\/11\/09) and in the Coimbra University, Coimbra, Portugal (Reference number: HUC-43-09). All study participants or their legal guardians provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PH, CS, DV, SG, TB, HL, and CB have nothing to disclose. AVP is recipient of a postdoctoral grant of the Beatriu de Pin\u00f3s program (2018-BP-00129) from the Ministry of Business and Knowledge of the Government of Catalonia, co-funded by the EU Horizon 2020 program under an MSCA grant agreement (801370). MS received funds from the Alzheimer Forschung Initiative (AFI, project no. 20026). IS received an institutional pharma grant (Roche) for a project of investigation on Multiple Sclerosis 2021 and consultations fees for speakers bureau and educational events from Roche, Biogen, and Merck; attended American Academy of Neurology; is supported by Roche; and is Member of the EAN Pannel in dementia Portuguese National Ethics committee. IB is funded by Grupo de Estudos de Envelhecimento Cerebral e Demencia, Sanofi-Genzyme, Funda\u00e7\u00e3o Ci\u00eancia e Tecnologia - FCT, and received honoraria from Merck S.A. JR is funded by the EU grant for blood donation of reconvalescence plasma after COVID19-infection. FL received funding from the ADDF (Alzheimer\u2019s Drug Discovery Foundation, grant 201810-2017419 related to this work) and is recipient of research grants from the Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) from the Government of Spain (grants CP16\/00041 and PI19\/00144). IZ received funding from the ADDF (Alzheimer\u2019s Drug Discovery Foundation, grant 201810-2017419) and the Robert Koch Institute through funds from the German Federal Ministry of Health (grant no. 1369\u2013341).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}